Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: An interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'

Anti-Cancer Drugs

Volumn 21, Issue 1, 2010, Pages 94-100

  Boeck, Stefan ^a   Vehling Kaiser, Ursula ^b   Waldschmidt, Dirk ^c   Kettner, Erika ^d   Märten, Angela ^e   Winkelmann, Cornelia ^f   Klein, Stefan ^g   Kojouharoff, Georgi ^b   Gauler, Thomas ^h   Fischer Von Weikersthal, Ludwig ^b   Clemens, Michael R ⁱ   Geissler, Michael ^j   Greten, Tim F ^k   Hegewisch Becker, Susanna ^b   Neugebauer, Sascha ^l   Heinemann, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Practice for Medical Oncology ^*  (Switzerland)

^c UNIVERSITY OF COLOGNE   (Germany)

^d Klinikum Magdeburg   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f Krankenhaus Lutherstadt Wittenberg   (Germany)

^g INSTITUTE OF PATHOLOGY   (Germany)

^h UNIVERSITY HOSPITAL ESSEN   (Germany)

ⁱ Trier Research Park   (Germany)

^j KLINIKUM ESSLINGEN   (Germany)

^k HANNOVER MEDICAL SCHOOL   (Germany)

^l WiSP Research Institute   (Germany)

more..

Author keywords

Capecitabine; Erlotinib; Gemcitabine; Pancreatic cancer

Indexed keywords

CAPECITABINE; ERLOTINIB; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CROSS-OVER STUDIES; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; GERMANY; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREAS, EXOCRINE; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; QUINAZOLINES;

EID: 74349087063     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833123ed     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Hochster HS, Haller DG, de Gramont A, Berlin JD, Philip PA, Moore MJ, et al. Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer. Cancer 2006; 107:676-685.
3. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-2413.
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical trials group. J Clin Oncol 2007; 25:1960-1966.
5. Cunningham D, Chau I, Stocken D, Davies C, Dunn J, Valle J, et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer [abstr PS11]. Eur J Cancer 2005; 3 (Suppl):12.
6. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007; 25:2212-2217.
7. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23:3509-3516.
8. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schoenekaes H, Rost A, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24:3946-3952.
9. Heinemann V, Labianca R, Hinke A, Louvet C. Increased survival using platinum analog combined with gemcitabine as compared to gemcitabine single agent in advanced pancreatic cancer (APC): pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 2007; 18:1652-1659.
10. Boeck S, Hoehler T, Seipelt G, Mahlberg R, Wein A, Hochhaus A, et al. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol 2008; 19:340-347.
11. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008; 8:82.
12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005; 353:123-132.
13. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the tarceva lung cancer investigation trial. J Clin Oncol 2007; 25:1545-1552.
14. Dragovich T, Huberman M, von Hoff DD, Rowinsky EK, Nadler P, Wood D, et al. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: a phase IB trial. Cancer Chemother Pharmacol 2007; 60:295-303.
15. Ouchi KF, Yanagisawa M, Sekiguchi F, Tanaka Y. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. Cancer Chemother Pharmacol 2006; 57:693-702.
16. Kulke MH, Blaszkowsky LS, Ryan DR, Clark JW, Meyerhardt JA, Zhu AX, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 2007; 25:4787-4792.
17. Meyerhardt JA, Zhu AX, Enzinger PC, Ryan DP, Clark JW, Kulke MH, et al. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol 2006; 24:1892-1897.
18. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27:2231-2237.
19. Gomez-Martin C, Camara JC, Cortes H, Jara C, Gravalos C, Rubio B, et al. A phase I study of erlotinib, bevacizumab and gemcitabine in patients with advanced pancreatic cancer [abstract]. J Clin Oncol 2007; 25 (Suppl):4611.
20. Tejpar S, Peeters M, Humblet Y, Gelderblom H, Vermorken J, Viret F, et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data [abstract]. J Clin Oncol 2007; 25 (Suppl):4037.
21. http://www.roche-trials.com/patient/trials/trial110855.html; (ClinicalTrials.govIdentifier: NCT00652366)
22. Hughes AN, O'Brien ME, Petty WJ, Chick JB, Rankin E, Woll PJ, et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 2009; 27:1220-1226.
23. Boeck S, Heinemann V. The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer. Future Oncol 2008; 4:41-50.
24. Boeck S, Heinemann V. Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer. J Clin Oncol 2008; 26:1178-1179.
25. Pelzer U, Kubica K, Stieler J, Schwaner I, Heil G, Görner M, et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 2008; 26 (Suppl):4508.
26. Boeck S,Wilkowski R, Bruns CJ, Issels RD, Schulz C, Moosmann N, et al. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology 2007; 73:221-227.